Zura Bio (NASDAQ:ZURA) Trading Down 7.9% – Should You Sell?

Zura Bio Limited (NASDAQ:ZURA)’s stock price fell 7.9% during mid-day trading on Wednesday . The company traded as low as $5.51 and last traded at $5.4310. 142,710 shares traded hands during trading, a decline of 83% from the average session volume of 831,630 shares. The stock had previously closed at $5.90.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ZURA shares. Chardan Capital raised their price target on shares of Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Wedbush reiterated an “outperform” rating and set a $15.00 price objective on shares of Zura Bio in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Finally, Oppenheimer reduced their target price on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Friday, March 20th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

Zura Bio Stock Performance

The firm has a fifty day moving average of $4.47 and a 200 day moving average of $5.29. The firm has a market capitalization of $488.16 million, a PE ratio of -4.76 and a beta of 0.03.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). Research analysts forecast that Zura Bio Limited will post -0.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Allworth Financial LP purchased a new position in Zura Bio in the fourth quarter valued at about $30,000. Scientech Research LLC purchased a new stake in Zura Bio during the 3rd quarter worth approximately $45,000. AQR Capital Management LLC acquired a new position in shares of Zura Bio in the 1st quarter valued at approximately $72,000. Bank of America Corp DE raised its position in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after purchasing an additional 9,966 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Zura Bio during the 3rd quarter valued at approximately $109,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.